METHODS
This single center, randomized nonblinded controlled noninferiority design trial was performed in a Jerusalem tertiary hospital labor and delivery suite with 5600 deliveries per year, an epidural analgesia rate of 59% and cesarean delivery rate of 21%. After receiving IRB and Ministry of Health approval (057708HMO), eligible women were approached for recruitment between February 2010 and August 2010 in the labor ward when the investigator was available. Written informed consent was obtained before enrollment. The trial was registered at www.clinicaltrials.gov (NCT00801047).
Eligible women included healthy, ASA physical status class I or II, age 18 to 40 years, body weight <110 kg, gestational age >36 completed weeks, with singleton pregnancy and vertex presentation. Women with the following criteria were excluded: contraindication to epidural analgesia, opioid administration in the previous 2 hours, previous uterine surgery, preeclampsia, inability to understand the consent form, nasal obstruction for any reason and medical indication for epidural analgesia (e.g., cardiac disease, suspected difficult airway), or nonreassuring fetal heart rate (FHR) tracing. Induction of labor (oxytocin or prostaglandin E2 suppository) and augmentation of established labor (oxytocin) before enrolment were not exclusion criteria.
Women were approached on arrival in the delivery suite or as soon as possible thereafter and gave verbal consent; however, they were not enrolled until they were in the active phase of labor, as determined by the attending obstetrician. Women were informed before study enrolment that conversion to the other treatment would be possible at any time during labor beginning 30 minutes after analgesia initiation with the study technique. Written informed consent was signed at the time of request for analgesia. Randomized treatment allocation was revealed when the woman was in active labor with cervical dilatation ≥2 cm and requesting analgesia, as determined by the obstetrician in attendance. Randomization and group allocation were determined: cards were divided into groups of 8 cards. Each group contained 4 allocation cards for remifentanil and 4 allocation cards for epidural analgesia (ratio 1:1), and 8 opaque envelopes numbered in groups from 1-8, 9-16, etc. were assigned to each group of cards. The cards were placed face down, manually shuffled, randomly selected, and then inserted into the numbered, opaque envelopes by a person not involved in the study. These envelopes were then sealed. Treatment assignment was revealed by breaking the seal of an envelope in consecutive order from number 1.
Laboring women randomized to the remifentanil group received remifentanil patient-controlled IV analgesia (PCIA); the bolus dose was titrated to effect from 20 mcg up to a maximum of 60 mcg as required; the lockout interval was initially set at 2 minutes, without a background infusion. The PCIA bolus/lockout interval was titrated to an end point of either patient comfort, or a maximal bolus dose of 60 mcg/minimal lockout interval of 1 minute by the recruiting anesthesiologist at any time during labor. The PCIA pump tubing was "piggybacked" into the distal most port of the mainline IV fluid tubing. The mainline tubing contained an antireflux valve designed to prevent remifentanil inadvertently backing up in the IV line during administration. The recruiting anesthesiologist (a resident performing a mandatory research project) remained by the woman's bedside until the end of treatment with remifentanil.
For women randomized to receive epidural analgesia, a 17-gauge Tuohy needle was inserted by the midline approach using loss of resistance to air at intervertebral space L3-4 or L2-3. An incremental initial loading dose of 15 mL of 0.1% bupivacaine with 50 mcg fentanyl was administered followed by patient-controlled epidural analgesia infusion of 0.1% bupivacaine with 2 mcg/mL fentanyl: basal infusion of 5 mL/h, patient-controlled bolus 10 mL, and lockout interval 20 minutes. Additional epidural bolus doses (either 0.1% bupivacaine 10 mL during the first stage of labor or 1% lidocaine 8 mL during the second stage of labor) were administered by the anesthesiologist to treat breakthrough pain. If epidural analgesia failed, the epidural catheter was reinserted. After epidural analgesia administration, the recruiting anesthesiologist remained by the woman's bedside for the first hour and then remained in the labor ward, dedicated to her care, until delivery.
Maternal safety aspects: Respiratory monitoring was performed using a Capnostream® capnograph (Oridion®, Jerusalem, Israel) with an oral-nasal cannula, sampling from both the nose and mouth (Oridion®). Laboring women receiving remifentanil were monitored throughout labor, whereas women receiving epidural analgesia were monitored for a minimum of 1 hour after induction of analgesia. This difference was due to attrition with the respiratory monitor throughout labor in the epidural group as women wished to remove the respiratory monitor and nasal prongs. However, women in the remifentanil group were encouraged to remain monitored for safety reasons. All women received continuous supplementary oxygen (2 liters/min) through an oral-nasal cannula throughout the respiratory monitoring period.
The respiratory monitor recorded continuous waveform end-tidal carbon dioxide (etco 2 ), respiratory rate, pulse oximetry (Spo 2 ) and heart rate. Carbon dioxide (CO 2 ) was monitored by continuously drawing gas through the sampling line to an infrared source and detector within a remote monitor. This device avoids significant entrainment of room air by sampling 50 mL/min; after measurement, the sample is defused into the environment. The small sampling volume reduces errors associated with traditional sidestream capnography. Dilution of sampled gas and blockage of the sampling line by water are potential sources of inaccurate measurements when large volumes are sampled. 8 All alarms were audible, but the beat-to-beat sound on the respiratory monitor was turned off so as not to alert the laboring women to changes. The settings of the Spo 2 alarm and respiratory rate alarm acted, for the purpose of the study, as an alert for potential impending apnea. Spo 2 <94%, respiratory rate below 8 breaths per minute, etco 2 ± 15 mm Hg from baseline or apnea longer than 20 seconds, activated an audible alarm. Throughout the respiratory monitoring period, the recruiting anesthesiologist was present in the labor room, maintaining visual contact with both the woman's face and respiratory monitor. Apnea triggered a staged intervention starting with a verbal reminder to breathe after 40 seconds, unless Spo 2 decreased below 90%, in which case the response was initiated earlier. If there was no response, a light tap was given on the woman's arm or shoulder in combination with a verbal command to take a deep breath. The anesthesia provider in the room manually documented potential causes of artifacts (e.g., uterine contractions, disconnections, removal of nasal prongs, eating, or drinking). In addition, the presence of the anesthesiologist fulfilled a United States Food and Drug Administration recommendation for a trained person to be present for monitored anesthesia care.
FHR was monitored to ensure neonatal safety using cardiotocography. 9 The local IRB required that remifentanil therapy be withdrawn in favor of alternative analgesia (epidural, nitrous oxide) if the FHR tracing became nonreassuring (decreased variability, bradycardia, or late decelerations). The IRB also required the presence of a neonatologist at each birth after remifentanil treatment, in case of neonatal cardiorespiratory depression.
Data Acquisition and Retrieval
Each woman was asked about antenatal class attendance and her plans for labor analgesia. Demographic and medical data were obtained from personal interviews before analgesia initiation and throughout labor. Physiological data were recorded from ongoing assessment of respiratory and fetal monitors. Maternal pain was assessed using an 11-point verbal numerical rating scale (NRS) of 0 to 10, where 0 is no pain and 10 is the worst pain imaginable. NRS pain scores were recorded before analgesia, 30 minutes after analgesia was administered, then hourly up to a total of 7 hours, and within 1 hour after delivery.
The respiratory monitor data were downloaded onto a USB memory stick. Lowest Spo 2 was noted during all apnea events. The number of apnea events was counted for each woman (respiratory rate of zero for at least 20 seconds). Apnea events for the remifentanil group were recorded throughout the entire labor as capnography was used for the labor duration in these women, and the Spo 2 signals were examined during all apnea events. The relationship between administered remifentanil dose and apnea was assessed. For apnea events, the interval examined for each apnea event included the start of the apnea episode until 40 seconds after the end of the apnea episode. Due to the respiratory monitoring protocol whereby the anesthesiologist intervened after 40 seconds of apnea, all apnea events >60-second duration were assumed to be artifacts and removed. The incidence and number of hypoxemic events (Spo 2 <94%) were counted for each woman. The mean Spo 2 per woman was used to compare between the 2 study groups. Numbers of alarm triggers were recorded for apnea, hypoxemia, and respiratory rate. Sedation scores were recorded hourly after initiating analgesia (4-point scale, 0 = spontaneous eye opening to 3 = unrousable). 10 Maternal satisfaction with analgesia was assessed using an NRS score (0-10) 30 minutes after analgesia administration and after delivery.
Maternal requests for additional analgesia were manually recorded in the research form hourly throughout labor. The investigator inquired whether opioid side effects (i.e., pruritus and/or nausea and vomiting) were present or absent. Oral temperature was measured both at the onset of analgesia and within 1 hour of delivery.
Cervical dilation was assessed by the midwife, and all changes were recorded until delivery. The time from requesting analgesia until 10-cm cervical dilation was also noted by the study anesthesiologist. Use of oxytocin to augment the labor was documented, as was mode of delivery. Decisions to perform operative delivery were made by the attending obstetrician based on standard practice. The duration of the first and second stages of labor were abstracted from the electronic medical record as recorded by the midwife. The first stage was defined as time from the first notation of a cervical dilatation >2 cm with regular contractions until the cervix was noted to be dilated to 10 cm.
After delivery, face-to-face follow-up was performed on the first postpartum day for both mother and child by one of the investigators (DS). Umbilical artery pH and base excess were abstracted from the medical record. Apgar scores at 1 and 5 minutes were determined by the midwife or pediatrician (neither were involved in the study). Neonatal interventions required in the immediate postnatal period (e.g., manual ventilation with bag/mask or supplemental oxygen) were noted. Umbilical artery pH and base excess were measured. Heart rate, respiratory rate, Spo 2 , and temperature were recorded by the neonatologist during the initial newborn assessment in the postnatal ward, approximately 30 to 60 minutes after delivery. Any exceptional event was recorded by the neonatologist.
Study End Points
The primary study objective was to demonstrate noninferiority of remifentanil labor analgesia compared with epidural analgesia in laboring women, measured by hourly assessment of NRS for pain throughout the duration of labor and maternal satisfaction. The secondary outcome was the incidence of apnea.
Statistical Methods

Sample Size
This study was designed to determine whether remifentanil analgesia in labor is noninferior to epidural analgesia with respect to the subject-reported pain using NRS. This efficacy end point was chosen rather than a potentially rarer safety end point. The sample size required to test this hypothesis with 90% power at a 1-sided 2.5% level of significance, assuming a standard deviation (SD) of 13 mm and a noninferiority margin of −15 mm, was estimated as 17 women per study group. The sample size was based on previous findings of 10 mm SD, where 1 NRS unit was assumed equivalent to 10 mm on the 100-mm visual analog scale. 11 That study reported a comparison of analgesic efficacy of a high versus low epidural dose for labor analgesia. For the current study, we elected to use the more conservative SD of 13 mm, (1.3 units), to increase the sample size. The noninferiority
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Effects of IV Remifentanil Vs Epidural for Labor margin of 15 mm (or 1.5 units) was selected since this was not considered to be a clinically significant difference in reported pain scores. A noninferiority test was used because epidural analgesia has been shown to be more effective than remifentanil analgesia and was not expected to be worse. Allowing for a 15% dropout rate, 20 subjects were randomized to each study arm. We assumed that the remifentanil analgesic effect was not inferior to the epidural analgesia effect if the lower limit of the 95% confidence interval (CI) of the difference between the epidural and remifentanil mean NRS scores was >−1.5 units, that is, −1.5 was not contained within the 95% CI of the difference. A lower NRS score is desirable; thus, a negative difference means that the epidural score is lower (better) than the remifentanil score.
Data Analysis
Data were analyzed using the intention-to-treat principle. Demographic data and baseline clinical characteristics were tabulated and compared between the 2 study groups. Continuous data are summarized by a mean and SD and compared with 2 sample t tests (respiratory rate, saturation, etco 2 , cervical dilatation, maternal satisfaction, temperature, duration of labor, birth weight, umbilical artery pH and base excess, neonatal assessments). Wilcoxon MannWhitney U was used for nonparametric tests for nonnormally distributed data after assessment for normality using Q-Q plots (number of respiratory, hypoxemia, apnea alarm occurrences per woman). Categorical data are presented as counts and percentages and compared with the χ 2 test or Fisher exact test (number of women with: apnea alarm triggered, requests for additional analgesia, nausea, pruritus, sedation, oxytocin augmentation, instrumental or cesarean delivery, neonatal resuscitation). Repeated measures analysis of variance was performed (SAS® PROC MIXED procedure) to model the NRS scores changes over time, in which the NRS score differences from baseline were modeled as a function of the baseline NRS, time, study group, and the study group * time interaction. LSMeans (model estimated means) for planned comparisons of the differences in NRS scores between the groups per time point were calculated from the interaction term and are presented with 95% confidence intervals (all Bonferroni adjusted). Several covariance structures were assessed in the model-building process; the compound symmetry structure had the lowest AIC (Akaike information criterion) value and was used in the final model. These 95% CIs were used to test the primary efficacy end point. A P value of 0.05 or less was considered statistically significant. Nominal P values are presented.
Data retrieved from the capnograph were analyzed by a mathematician using Matlab version 7.9.0, Natick, MA: The MathWorks Inc., 2003. Due to the 1-hour length of the epidural data strip, group allocation was implicitly obvious; hence, the mathematician was not blinded to group Figure 1 . Trial enrollment profile. The exclusion was due to obstetrician concern regarding potential effects of remifentanil patient-controlled IV analgesia on cardiotocography monitoring, which demonstrated fetal heart rate nonvariability, after enrollment but before analgesia.
allocation. However, she was blinded to our study hypothesis that remifentanil was noninferior to epidural analgesia and that remifentanil may have respiratory effects different from those seen with epidural analgesia. For the analysis, the mean ± SD for each recorded signal (etco 2 , respiratory rate, and Spo 2 ) over the first hour after analgesia initiation were used for each woman as a summary statistic. The data were compared between groups using 2 sample t tests. The incidence of occurrence of an alarm trigger for each woman was compared using Fisher exact test. Median, range [IQR], number of alarm triggers per woman are reported. The correlation between apnea and the total remifentanil dose were analyzed by Spearman Rank Correlation.
RESULTS
During the study period, 144 women were approached, 40 women consented to enroll, and 1 was subsequently excluded Figure 1 . Demographic characteristics are reported in Table 1 .
Remifentanil was found to be inferior to epidural analgesia with respect to the NRS scores at all time points; the observed difference in NRS was greater than the expected −1.5 unit difference in NRS scores. NRS pain scores are presented in Table 2 . There was no significant difference between baseline NRS pain scores in the 2 groups. Scores were significantly lower at 30 minutes in both groups (adjusted mean [± SD] change for remifentanil −4.7 ± 0.6, epidural −7.2 ± 0.6, P < 0.0001). Both remifentanil and epidural analgesia resulted in a significant decrease from baseline NRS scores over time (Fig. 2) . Assessing the change in NRS scores over 6 hours via model of repeated measures analysis of variance, remifentanil was significantly less effective than epidural analgesia, including at the postpartum assessment.
One woman allocated to the epidural analgesia group refused to use the respiratory monitor; therefore, these data are reported for 19 women per group. Apnea occurred a total of 9 times in 5 women during the first hour in the remifentanil group and did not occur in any woman in the The figure depicts the model estimated mean (LSmeans) (with error bars) changes from baseline for both study groups at each time point. Since the figure depicts model estimated means the SE of the estimate is presented. The change from baseline in numerical rating scale (NRS) score was modeled using repeated measures analysis of variance model. NRS score differences from baseline were modeled as a function of the baseline NRS time, group, and the group * time interaction. The baseline values were similar in both groups (remifentanil 8.4 ± 1.5, epidural 8.7 ± 1.2, P = 0.52). The NRS score is reduced in both groups compared with baseline. The number of data points used at each time is shown in the raw data, Table 2 , and the attrition is manifested in the figure by the longer error bars. Numerical rating scale (NRS) score was modeled as a function of time, group, and the group * time interaction. LSMeans (model estimated means) for the NRS scores in each group per time point presented in Figure 2 and the differences between the groups at each time point were estimated from the model (from the interaction term) and are presented with respective Bonferroni adjusted 95% confidence intervals, and level of significance. The null hypothesis of noninferiority is tested at each time point via the CIs, if −1.5 is not contained within the interval the remifentanil group is deemed noninferior to the epidural group. This did not occur at any time point.
epidural group (Table 3 ). The hypoxemia alarm data and other respiratory variables are reported in Table 3 . In the remifentanil group, 27 apnea events occurred in 9 women over the duration of monitoring; 14 events occurred in the first 2 hours of remifentanil administration. Three women had 1 apnea event, 1 had 2 events, 2 had 3 events, 2 had 4 events, and 1 woman had 8 apnea events (all after the first 2 hours of administration). There was no correlation between total remifentanil dose per kilogram body weight (independent variable) and the number of apnea episodes divided by recording length in minutes (dependent variable), R = 0.13, P = 0.30.
The Spo 2 signals were examined during all 27 apnea events in remifentanil women (Fig. 3) . Spo 2 remained above 94% throughout 16/27 (59.3%) apnea events recorded in the remifentanil group and above 92% throughout 18/27 (66.7%) apnea events. Only in 6/27 (22.2%) events did the Spo 2 decrease below 94% before apnea occurred. Figure 4 shows a typical apnea event lasting over 30 seconds with time-matched capnography and Spo 2 graphs.
Most women in both groups were rated as awake on the 4-point sedation scale, except 6/19 (32%) in the remifentanil group who were easily arousable and 1 in the epidural group (5%) ( Table 4) . 10 Delivery modes were similar in both groups (Table 5) .
Two neonates in the remifentanil group and none in the epidural group required an intervention after delivery (Table 6 ). One neonate received stimulation and supplemental oxygen, after the mother received a total labor dose of 3890 mcg remifentanil over 281 minutes (4.7 hours). The other neonate required stimulation and manual ventilation using bag and mask, with recovery within 30 seconds after maternal administration of 3415 mcg remifentanil throughout labor over 174 minutes (2.9 hours). Both newborns quickly recovered without further interventions; 1-minute Apgar scores were 7 and 6, and 5-minute Apgar scores were 8 and 10, respectively. There were no reported adverse events in the neonatal ward in either group.
DISCUSSION
This study aimed to show that IV remifentanil as a labor analgesic is not inferior to epidural analgesia. Although both are effective at reducing NRS pain scores, remifentanil is inferior to epidural with regard to the magnitude of the pain score reduction. Pain scores were higher at all time points than the expected −1.5 unit difference in NRS scores. The current study demonstrates respiratory morbidity with remifentanil which may be an unacceptable risk. The data retrieved from the capnography monitor report apnea without desaturation (Sao 2 <94%), suggesting that pulse oximetry is inadequate as an early alert to apnea.
Epidural analgesia has been shown to reduce NRS scores to a greater extent than remifentanil; however, women Epidural, n = 20 P Cervical dilatation at onset of analgesia (cm) e all crossovers were due to failure of allocated analgesia, and there were no crossovers due to fetal heart rate abnormality. f Fisher exact test. www.anesthesia-analgesia.org
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Effects of IV Remifentanil Vs Epidural for Labor receiving remifentanil expressed their satisfaction with being able to "control" their analgesia and adjust it according to their need. 7, 12 Involvement in decision making may override other factors influencing satisfaction, including pain. 13 The introduction of routinely available remifentanil PCIA as an alternative to epidural analgesia in 1 labor unit led to a decrease in the epidural rate. 2 Remifentanil PCIA has been proposed as a viable routine alternative to epidural analgesia in the labor ward. 14 Maternal respiratory side effects of remifentanil have been reported previously. 5, 6, 15 Hypoxemia has been reported also with systemic meperidine analgesia. Comparison of meperidine and nitrous oxide to remifentanil show the latter provided better analgesia with fewer adverse effects. 1, 16, 17 However, 1 lifethreatening respiratory complication of remifentanil in labor analgesia has been reported in the literature; other cases may not be reported because of publishing bias. 15 Administration of supplemental oxygen in our study may have delayed the occurrence of desaturation; however, it did not prevent apnea. Oxygen supplementation during remifentanil administration is recommended in laboring women by some investigators. 6, 7, 18 Remifentanil resulted in higher mean etco 2 than epidural analgesia, although the difference was not significant. Since both groups received oxygen during the entire monitoring period, it is not reasonable to assume that supplemental oxygen was an additional cause for hypercarbia in women receiving remifentanil. Both Tveit et al. 6 and Volmanen et al. 7 used pulse oximetry and found desaturation at effective doses of remifentanil in labor but did not report whether apnea occurred. The Food and Drug Administration requires that remifentanil be administered only in a monitored anesthesia care unit with continuous presence of personnel trained in airway management, as was done in the current study. 19 Hypoxemic and apneic events in the remifentanil group during labor were seen both during and after the first 2 hours and occurred throughout labor over a wide range of doses. Thus, a "safe" dose or duration of administration of remifentanil cannot be recommended based on the results presented in this study. This study is one of the few studies which offered remifentanil from time of request for analgesia up until delivery. The bolus dose of remifentanil in the current study was adjustable up to 60 mcg. Increasing the remifentanil dose during labor can avoid regression to baseline pain levels that may be observed when a fixed remifentanil dose is used. 4, 6, 18, 20 Opioid-induced hyperalgesia or tolerance may play a role in increased requirements. Both bolus and continuous infusion have been described, although continuous infusion may provide superior analgesia. 5, 21 This study supports previous findings in which no correlation between dose (adjusted for body weight) and hypoxemia was found. 6 The current study supports previous findings that maternal remifentanil may be safe for neonates, although the study sample size is small. Remifentanil does cross the placenta but is rapidly metabolized by blood and tissue esterases in the fetus. 22, 23 Remifentanil PCIA may currently be the optimal alternative among opioid analgesics to minimize adverse neonatal side effects. 24 Our study design had several limitations. Postevent analysis of data obtained from the respiratory monitor was complicated by some artifacts, which were not noted by the anesthesiologist monitoring the patient, caused, for example, by hand squeezing interfering with the Spo 2 probe during contractions. Connecting the Spo 2 probe elsewhere was considered inconvenient for the woman. The complexity of analyzing apnea events was also confounded by women temporarily removing the nasal prongs to scratch her nose, drinking, eating, or breath holding during a contraction. Nonbiased identification of artifacts during labor may have been possible with an additional observer throughout labor, although this was considered an unacceptable invasion of privacy in the study institution. The data from the current study population suggest the different rate of apnea occurrence in the 2 groups was unlikely to be by chance (P < 5%). However, the study sample size was not based upon apnea as an outcome. This difference in apnea occurrence would be expected to be greater were a larger sample to be used. The accurate measurement of etco 2 requires a closed circuit. However, the significant entrainment of room air was avoided by using a capnograph providing a breath sampling rate of 50 mL/min to the device. Neither laboring women nor the anesthesiologist were blinded to the study group assignment. This would have required placing an epidural catheter in all women. Most likely, both the woman and the treating team would have guessed treatment assignment. Furthermore, a potential benefit to encourage enrollment was the fact that epidural catheter insertion was unnecessary. To avoid bias, study participants, the obstetricians/nurse-midwives, and the mathematician performing respiratory analyses were not aware of the primary study end points. Laboring women were told that the study was performed to assess the feasibility of using remifentanil in the labor ward. (Interestingly, many women who received epidural analgesia were not delighted with their group allocation.) The epidural group underwent respiratory monitoring for only 1 hour rather than during the entire labor. Prestudy testing suggested that there would be high attrition with respiratory monitoring in the epidural group.
Apnea alone may not be an unacceptable risk of remifentanil analgesia if it is easily resolved. However, the natural history of these apnea events was not evaluated in the current study. We only evaluated the occurrence of apnea using bolus doses of remifentanil. It is possible that a continuous infusion, or a combination of bolus doses and a continuous infusion, may have a different impact on the occurrence of apnea.
In conclusion, remifentanil administration during labor requires appropriate monitoring to detect and alert for maternal apnea. Capnography may be used to identify respiratory depression, and simple interventions were sufficient to restore adequate ventilation when apnea occurred in our population. Although remifentanil analgesia is inferior to epidural analgesia, it may provide a satisfactory alternative when epidural analgesia is not desired or permitted. Future studies should consider administration of remifentanil in the labor ward with particular reference to respiratory monitoring and manpower requirements. E DISCLOSURES Name: Daniel Stocki, MD. Contribution: This author is the principal investigator, helped study design, recruitment, and performance, collect the data, analyze the data, and prepare the manuscript.
